Ninlaro mechanism of action?

How does Ninlaro work (mechanism of action)?

Ninlaro (ixazomib) is a proteasome inhibitor. It blocks the 20S proteasome, which prevents the breakdown of proteins that cancer cells rely on to survive. By disrupting this protein degradation pathway, Ninlaro can trigger stress responses and promote cell death in multiple myeloma cells [1].

What does blocking the proteasome do to multiple myeloma cells?

Multiple myeloma cells depend heavily on proteasome activity to manage abnormal or rapidly produced proteins. Inhibiting the proteasome disrupts that balance, leading to accumulation of proteins inside the cell and activation of cell-death mechanisms [1].

How is Ninlaro different from other proteasome inhibitors?

Ninlaro is in the same drug class as other proteasome inhibitors, but it is an oral (capsule) form of ixazomib. Like other proteasome inhibitors, its key mechanism is proteasome inhibition, but the route of administration and compound formulation differ [1].

Does Ninlaro have a role in combination therapy?

Ninlaro is used with other anti-myeloma agents in standard regimens (for example, with lenalidomide and dexamethasone, or with other combinations depending on treatment line). These partners don’t change its core mechanism; they work through different pathways while Ninlaro continues to inhibit the proteasome [1].

Sources

1. [Ninlaro (ixazomib) Prescribing Information, Takeda] (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)